<DOC>
	<DOCNO>NCT02569723</DOCNO>
	<brief_summary>This pilot clinical trial study well carbon C 14 oxaliplatin microdosing assay work predict exposure sensitivity oxaliplatin-based chemotherapy patient colorectal cancer spread place body usually cure controlled treatment . Drugs use chemotherapy , oxaliplatin , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Carbon C 14 radioactive form carbon , exist nature body low level . Microdose carbon C 14 oxaliplatin diagnostic assay may help doctor understand well patient respond treatment develop individualize oxaliplatin dose patient colorectal cancer .</brief_summary>
	<brief_title>Oxaliplatin Microdosing Assay Predicting Exposure Sensitivity Oxaliplatin-Based Chemotherapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate feasibility [ 14C ] ( carbon C 14 ) oxaliplatin microdose clinical assay predict oxaliplatin exposure . SECONDARY OBJECTIVES : I . To estimate degree [ 14C ] oxaliplatin microdose predict observe pharmacokinetics standard dose oxaliplatin . II . To validate intrapatient variation exposure [ 14C ] oxaliplatin microdose less 5 % . III . To detect level oxaliplatin-deoxyribonucleic acid ( DNA ) adduct induced oxaliplatin microdosing peripheral blood mononuclear cell ( PBMCs ) , correlate result patient response progression free survival oxaliplatin-based chemotherapy . IV . To develop preliminary safety data [ 14C ] oxaliplatin microdosing future study . OUTLINE : Patients receive carbon C 14 oxaliplatin microdose intravenously ( IV ) 120 minute . Beginning 4 week initial carbon C 14 oxaliplatin microdose administration , patient receive FOLFOX comprise leucovorin calcium IV , fluorouracil IV 2 hour ( 46-48 hour via ambulatory infusion pump day 1 2 ) , oxaliplatin ( contain carbon C 14 microdose course I ) IV 2 hour day 1 . Courses repeat every 14 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically cytologically confirm locally advanced metastatic colon rectal adenocarcinoma Intent treat patient leucovorin calcium , fluorouracil , oxaliplatin ( FOLFOX ) chemotherapy regimen contain fluorouracil ( 5FU ) , leucovorin , oxaliplatin accord clinical standard practice ; intent dose oxaliplatin 85 mg/m^2 every 2 week basis Treatment additional Food Drug Administration ( FDA ) approve biologic agent ( i.e . bevacizumab , cetuximab , panitumumab ) allow accord standard practice Prior radiation surgery allow , finish least 2 week prior study enrollment ; participant prior radiation therapy , least one measurable lesion outside radiation field available evaluation response chemotherapy Any number prior therapy oxaliplatin allow Zubrod performance status equal le 2 ( Karnofsky equal great 50 % ) Life expectancy least 3 month Absolute neutrophil count great equal 1,500/microL Platelets great equal 100,000/microL Total bilirubin le 3 x institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase ) less equal 5 x ULN Creatinine le 1.5 x ULN Women child bear potential must pregnant ; prestudy pregnancy test must negative Women childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry 30 day study participation Men must agree use adequate contraception ( barrier method abstinence ) prior study entry 30 day study participation Ability understand willing sign write informed consent document Prior treatment oxaliplatin Patients must receive concomitant radiation Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Participants pregnant nursing Participants allergic platinum agent Participants grade 1 peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>